{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal UMC119-06",
            "NStudiesAvail": 430108,
            "NStudiesFound": 5,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 5,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "60 Years"
                        ],
                        "NCTId": [
                              "NCT04914403"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intravenous Infusion of UMC119-06-05 in Elderly Subjects With Mild to Moderate Frailty Syndrome."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Meridigen Biotech Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "UMC119-06-05-FS-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "40 Years"
                        ],
                        "NCTId": [
                              "NCT04206007"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Meridigen Biotech Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "UMC119-06-COPD-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "90 Years"
                        ],
                        "MinimumAge": [
                              "40 Years"
                        ],
                        "NCTId": [
                              "NCT04893174"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intra Articular (IA) Injection of UMC119-06-05 in Adult Subjects With Mild to Moderate Knee Osteoarthritis(KOA)."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Meridigen Biotech Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "UMC119-06-05-KOA-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT04097652"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Ischemic Stroke."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Meridigen Biotech Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "UMC119-06-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT04347967"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS)."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Meridigen Biotech Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "UMC119-06-ARDS-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}